Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

NCT04860960
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Oakland, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

NCT00575159
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
GSK189075, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

Preventing Asthma in High Risk Kids

NCT02570984
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
View directory record Official record
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

NCT03959189
View directory record Official record
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional

Dose Finding Study for QAW039 in Asthma

NCT01437735
View directory record Official record
Conditions
Asthma
Interventions
QAW039, Montelukast, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Encinitas, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646
View directory record Official record
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

NCT04147260
View directory record Official record
Conditions
Healthy
Interventions
BI 730357, Placebo to match BI 730357, Ciprofloxacin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma

NCT02371746
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bioequivalence Study on Vitamin C in Healthy Adults

NCT03562988
View directory record Official record
Conditions
Dietary Exposure
Interventions
Vitamin C gummy, Vitamin C tablet
Dietary Supplement
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 24, 2026, 6:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Placebo, Apremilast
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 24, 2026, 6:51 PM EDT
Not listed Phase 4 Interventional

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385
View directory record Official record
Conditions
Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions
Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Up to 18 Hours
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 24, 2026, 6:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 24, 2026, 6:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
71
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

NCT04124042
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
XT-150, Placebo
Biological · Drug
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
45 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
La Mesa, California • Napa, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing to Improve Oral Hygiene in Adolescent Orthodontic Patients

NCT07164989
View directory record Official record
Conditions
Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
Interventions
Motivational Interviewing-Based Counseling, Standard Oral Health Education
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 24, 2026, 6:51 PM EDT
Terminated Phase 2 Interventional

Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

NCT03700723
View directory record Official record
Conditions
Coagulopathy
Interventions
Resusix, FP24 (Frozen Plasma)
Biological
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 24, 2026, 6:51 PM EDT
Not yet recruiting Not applicable Interventional

The Immediate Effects of First Rib Mobilization on Pain and Range of Motion in Patients With Shoulder Pain

NCT07064772
View directory record Official record
Conditions
Shoulder Pain
Interventions
First Rib Mobilization, Sham Comparator
Other
Lead sponsor
Andrews University
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Annville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

NCT01244139
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 24, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

NCT02100631
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
46 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
16
States / cities
Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 24, 2026, 6:51 PM EDT